BiosimilarBiological
JHL1101 clinical trials
Also written JHL1101.
A product of Rituximab; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 1
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
JHL Biotech, Inc. (3)
Studies
Open first, then newest update. How each study uses JHL1101 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid ArthritisTerminatedPhase 1JHL Biotech, Inc.NCT03161457Written as JHL1101
- A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedPhase 3JHL Biotech, Inc.NCT03670901Written as JHL1101
- A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsTerminatedPhase 1JHL Biotech, Inc.NCT03670888Written as JHL1101